Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Multi-centric Castleman's Disease 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Classic Follicular Lymphoma 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1Amyloidosis 1

Interventions

Cyclophosphamide 63fludarabine phosphate 40Peripheral Blood Stem Cell Transplantation 34Vincristine 30Methotrexate 30Etoposide 29Cytarabine 28Dexamethasone 27Whole-Body Irradiation 25Doxorubicin 25Mycophenolic Acid 23Prednisone 22Tacrolimus 21Filgrastim 21Busulfan 19Antilymphocyte Serum 18venetoclax 17nelarabine 17Cyclosporine 17Calcium Dobesilate 17merphos 15Rituximab 14Radiotherapy 14Methylprednisolone 13Bortezomib 13pegaspargase 12dexamethasone acetate 11dexamethasone 21-phosphate 11Melphalan 11prednylidene 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Hyaluronoglucosaminidase × Clear all
NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Eastern Cooperative Oncology Group

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡